On September 3, 2025 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, reported that John Celebi, President and Chief Executive Officer, will participate in 1×1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025 (Press release, Sensei Biotherapeutics, SEP 3, 2025, View Source [SID1234655734]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
An on-demand corporate presentation will be available here on September 5, 2025, at 7:00 a.m. ET. A replay of the webcast will be available in the Investors section of the Sensei website for approximately 90 days following the event.